Despite promising clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant difficulty from pharmacy benefit managers. The companies are typically building barriers to reimbursement, such as significant cost restrictions and prior authorization that hinder user opportunity. Ma